LEO 32731

Drug Profile

LEO 32731

Alternative Names: LEO32731; LP-0058

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator LEO Pharma
  • Class Antipsoriatics
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 10 stimulants; Interleukin 5 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I Atopic dermatitis

Most Recent Events

  • 25 Jul 2017 LEO Pharma initiates enrolment in a phase I trial in Healthy volunteers in United Kingdom (NCT03231124)
  • 31 May 2017 LEO Pharma initiates a phase I drug interaction trial in Healthy volunteers in Germany (NCT03126578)
  • 26 Apr 2017 LEO Pharma plans a phase I drug interaction trial in Healthy volunteers in Germany (NCT03126578)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top